Med Device was Angiodynamics’s largest product and service line in fiscal 2026, bringing in $145.09M of $274.92M (53%).
| Product and Service | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peripheral Vascular | — | — | — | — | |||||||||||
| Med Device | $198.38M | $161.13M | $141.73M | $145.09M | |||||||||||
| Access | — | — | — | — | |||||||||||
| Med Tech | $84.33M | $90.36M | $109.25M | $129.83M | |||||||||||
| Vascular Access | — | — | — | — | |||||||||||
| Endovascular Therapies | — | — | — | — | |||||||||||
| Oncology | — | — | — | — | |||||||||||
| Oncology Surgery | — | — | — | — | |||||||||||
| Supply Agreement | — | — | — | — | |||||||||||
| Total | $282.71M | $251.49M | $250.98M | $274.92M |
Angiodynamics brought in $274.92M from its two product and service lines in fiscal 2026, the year ended May 31, 2026. That is less than the $320.17M it reports by segment, so these lines do not cover all of its revenue. Med Device was the largest at $145.09M (52.8%), ahead of Med Tech at $129.83M (47.2%).
Compared with fiscal 2025, Med Tech grew 18.8% to $129.83M and Med Device grew 2.4% to $145.09M.
United States was Angiodynamics’s largest region in fiscal 2026, bringing in $145.09M of $170.22M (85%).
| Geography | FY 2012 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $198.38M | $161.13M | $141.73M | $145.09M | ||||||||||
| International | $43.68M | $36.39M | $24.12M | $25.13M | ||||||||||
| Total | $242.07M | $197.51M | $165.85M | $170.22M |
Angiodynamics brought in $170.22M from its two regions in fiscal 2026, the year ended May 31, 2026. That is less than the $320.17M it reports by segment, so these regions do not cover all of its revenue. United States was the largest at $145.09M (85.2%), ahead of International at $25.13M (14.8%).
Compared with fiscal 2025, International grew 4.2% to $25.13M and United States grew 2.4% to $145.09M.
Med Device was Angiodynamics’s largest segment in fiscal 2026, bringing in $170.22M of $320.17M (53%).
| Segment | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|
| Med Device | $242.07M | $197.51M | $165.85M | $170.22M |
| Med Tech | $96.69M | $106.40M | $126.65M | $149.95M |
| Total | $338.75M | $303.91M | $292.50M | $320.17M |
Angiodynamics brought in $320.17M from its two segments in fiscal 2026, the year ended May 31, 2026. That was up 9.5% from $292.50M in fiscal 2025. Med Device was the largest at $170.22M (53.2%), ahead of Med Tech at $149.95M (46.8%).
Compared with fiscal 2025, Med Tech grew 18.4% to $149.95M and Med Device grew 2.6% to $170.22M. From fiscal 2023 to 2026, combined revenue from these segments fell from $338.75M to $320.17M, a compound annual decline of 1.9%. Med Device's share of the total fell from 71.5% to 53.2%.
Angiodynamics (ANGO) reports its revenue by product and service, by geography and by segment. In fiscal 2026, Med Device was its largest product and service line, bringing in $145.09M (52.8% of the total), followed by Med Tech at $129.83M (47.2%).
Med Device was Angiodynamics' largest product and service line in fiscal 2026, bringing in $145.09M, or 52.8% of the $274.92M total across its two product and service lines.
United States was Angiodynamics' largest region in fiscal 2026, bringing in $145.09M, or 85.2% of the $170.22M total across its two regions.
Med Device was Angiodynamics' largest segment in fiscal 2026, bringing in $170.22M, or 53.2% of the $320.17M total across its two segments.
Med Tech grew faster than Med Device in fiscal 2026, up 18.8% from $109.25M to $129.83M. Med Device grew 2.4% to $145.09M.
Every figure comes from Angiodynamics' annual financial filings, as reported. Each line keeps the name Angiodynamics gives it, and years follow its fiscal calendar.
Angiodynamics' revenue by product and service goes back to fiscal 2012, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.